Endonovo Therapeutics (ENDV) 10-Q/A 27 May 16 2016 Q1 Quarterly report (amended) Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2016	May. 20, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	ENDONOVO THERAPEUTICS, INC.
Entity Central Index Key	1,528,172
Amendment Flag	true
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		109,616,075
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	Yes
Is Entity's Reporting Status Current?	Yes
Amendment Description	Amendment #1

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Cash	$ 108,893	$ 41,473
Other current assets	137,420	336,233
Total current assets	246,313	377,706
Property Plant and Equipment, net	27,699	31,657
Total Assets	274,012	409,363
Current Liabilities
Accounts payable and accrued expenses	4,222,997	3,990,185
Short term advances	0	3,605
Notes payable, net of discounts of $149,775 as of March 31, 2016 and $321,961 as of December 31, 2015	1,178,975	1,261,790
Notes payable - related party	245,000	245,000
Derivative liability	3,340,633	3,973,542
Current portion of long term loan	12,121	12,031
Total current liabilities	8,999,726	9,486,153
Notes payable, net of discounts of $693,390 as of March 31, 2016 and $477,346 as of December 31, 2015	119,110	27,654
Long term loan	13,552	16,616
Acquisition payable	155,000	155,000
Total liabilities	9,287,388	9,685,423
Shareholders' deficit
Super AA super voting preferred stock, $0.0001 par value, 1,000,000 authorized and 1,000 issued and outstanding	0	0
Common stock, $.0001 par value; 250,000,000 shares authorized; 108,289,265 and 104,803,401 shares issued and outstanding as of March 31, 2016 and December 31, 2015	10,830	10,479
Additional paid-in capital	4,939,438	3,773,642
Stock subscriptions	(1,570)	(1,570)
Accumulated deficit	(13,962,074)	(13,058,611)
Total shareholders' deficit	(9,013,376)	(9,276,060)
Total Liabilities and Shareholders' Deficit	$ 274,012	$ 409,363

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Common Stock
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	108,289,265	104,803,401
Common stock, shares outstanding	108,289,265	104,803,401
Discounts on current notes payable	$ 149,775	$ 321,961
Discounts on long term notes payable	$ 693,390	$ 477,346
Super AA super voting preferred stock
Super AA super voting preferred stock, par value	$ 0.0001	$ 0.0001
Super AA super voting preferred stock, authorized	1,000,000	1,000,000
Super AA super voting preferred stock, issued	1,000	1,000
Super AA super voting preferred stock, outstanding	1,000	1,000

Condensed Consolidated Statemen

Condensed Consolidated Statement of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Income Statement [Abstract]
Revenues, net	$ 0	$ 2,745
Cost of goods sold	0	824
Gross profit	0	1,921
Operating expenses	1,402,120	433,554
Loss from operations	(1,402,120)	(431,633)
Other income (expense)
Change in fair value of derivative liability	1,024,602	0
Gain on extinguishment of debt	133,038	0
Interest expense, net	(658,983)	(48,522)
Other income (expense), total	498,657	(48,522)
Loss before income taxes	(903,463)	(480,155)
Provision for income taxes	0	0
Net loss	$ (903,463)	$ (480,155)
Basic and diluted loss per share	$ (.01)	$ (.01)
Weighted average common share outstanding:
Basic and diluted	106,567,261	84,824,577

Condensed Consolidated Stateme5

Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Operating activities:
Net loss	$ (903,463)	$ (480,155)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization expense	3,958	3,640
Fair value of notes issued for services	518,457	2,304
Fair value of equity issued for services	529,456	1,766
Non-cash interest	115,000	0
Change in fair value of derivative liability	(1,024,602)	0
Loss (gain) on extinguishment of liabilities	(133,038)	0
Changes in assets and liabilities:
Other current assets	200,000	2,000
Accounts payable and accrued expenses	269,363	276,609
Net cash used in operating activities	(424,869)	(193,836)
Investing activities:
Net cash used in investing activities	0	0
Financing activities:
Proceeds from the issuance of notes payable	285,000	212,500
Proceeds from related pary short term advances	5,508	7,755
Proceeds from issuance of common stock	366,275	177
Repayments on notes payable	(125,000)	0
Repayment of prepayment premium on note payable	(26,220)	0
Repayments on related parties short term advances	(10,300)	0
Payment against long term loan	(2,974)	(1,936)
Net cash provided by financing activities	492,289	218,496
Net increase in cash	67,420	24,660
Cash, beginning of year	41,473	988
Cash, end of period	108,893	25,648
Supplemental disclosure of cash flow information:
Cash paid for interest	12,383	0
Cash paid for income taxes	0	0
Non Cash Investing and Financing Activities:
Conversion of notes payable and accrued interest to common stock	$ 269,416	$ 328,138

Condensed Consolidated Stateme6

Condensed Consolidated Statement of Shareholders' Deficit (Unaudited) - 3 months ended Mar. 31, 2016 - USD ($)	Series AA Preferred Stock	Common Stock	Additional Paid-in Capital	Common Stock Subscription Receivable	Retained Earnings	Total
Beginning balance at Dec. 31, 2015	$ 0	$ 10,479	$ 3,773,642	$ (1,570)	$ (13,058,611)	$ (9,276,060)
Beginning balance, shares at Dec. 31, 2015	1,000	104,803,401
Shares issued for cash	$ 0	$ 51	106,973	0	0	107,024
Shares issued for cash, shares	0	512,273
Private placement units issued for cash	$ 0	$ 98	271,152	0	0	271,250
Private placement units issued for cash, shares	0	975,827
Share issued for services	$ 0	$ 106	492,700	0	0	492,700
Share issued for services, shares	0	1,051,504
Shares issued with notes payable and extensions	$ 0	$ 8	25,643	0	0	25,643
Shares issued with notes payable and extensions, shares	0	70,110
Private placement units issued for conversion of notes payable and accrued interest	$ 0	$ 88	269,328	0	0	269,416
Private placement units issued for conversion of notes payable and accrued interest, shares	0	876,150
Net loss	$ 0	$ 0	0	0	(903,463)	(903,463)
Ending balance at Mar. 31, 2016	$ 0	$ 10,830	$ 4,939,438	$ (1,570)	$ (13,962,074)	$ (9,013,376)
Ending balance, shares at Mar. 31, 2016	1,000	108,289,265

Note 1 - Organization and Natur

Note 1 - Organization and Nature of Business	3 Months Ended
	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Note 1 - Organization and Nature of Business	Note 1 - Organization and Nature of Business Endonovo Therapeutics, Inc. and Subsidiaries (the “Company” or “ETI”) is primarily focused in the business of biomedical research and development, particularly in regenerative medicine, which has included the development of its proprietary square wave form device. The Company has historically been involved with intellectual property licensing and commercialization. Basis of Presentation and Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements have been presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Article 8 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. The condensed consolidated financial statements as of March 31, 2016 and 2015 are unaudited; however, in the opinion of management such interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the periods presented. The results of operations for the period presented are not necessarily indicative of the results that might be expected for future interim periods or for the full year. The consolidated financial statements of the Company include the accounts of ETI and IPR as of March 14, 2012; Aviva as of April 2, 2013; and WeHealAnimals as of November 16, 2013. All significant intercompany accounts and transactions are eliminated in consolidation. Going Concern These accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for a period following the date of these consolidated financial statements. The Company has raised approximately $650,000 in debt and equity financing for the period January 1, 2016 to March 31, 2016. The Company is raising additional capital through debt and equity securities in order to continue the funding of its operations. However, there is no assurance that the Company can raise enough funds or generate sufficient revenues to pay its obligations as they become due, which raises substantial doubt about our ability to continue as a going concern. No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management and has initiated a private placement offering to raise capital through the sale of its common stock and is seeking out profitable companies. Although, uncertainty exists as to whether the Company will be able to generate enough cash from operations to fund the Company’s working capital needs or raise sufficient capital to meet the Company’s obligations as they become due, no adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. Net Income (Loss) per Share For the three month period ending March 31, 2016, the Company had 7,747,422 of weighted average common shares relating to the convertible debt, under the if-converted method, however, these shares are not dilutive because the Company recorded a loss during the fiscal quarter. For the three months ended March 31, 2015, the Company had no dilutive securities. Recent Accounting Standard Updates The Company is not aware of any recently issued accounting pronouncements that when adopted will have a material effect on the Company’s financial position or results of its operations.

Note 2 - Property, Plant and Eq

Note 2 - Property, Plant and Equipment	3 Months Ended
	Mar. 31, 2016
Property, Plant and Equipment [Abstract]
Note 2 - Property, Plant and Equipment	Note 2 – Property, Plant and Equipment The following is a summary of equipment, at cost, less accumulated depreciation at March 31, 2016 and December 31, 2015: March 31, December 31, 2016 2015 Autos $ 64,458 $ 64,458 Medical equipment 5,000 5,000 Other equipment 8,774 8,774 78,232 78,232 Less accumulated depreciation 50,533 46,575 $ 27,699 $ 31,657

Note 3 - Notes Payable and Long

Note 3 - Notes Payable and Long Term Loan	3 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Note 3 - Notes Payable and Long Term Loan	Note 3 - Notes Payable and Long Term Loan Notes Payable During the three months ended March 31, 2016, the Company issued a Convertible Note (“Variable Note”) with an original term of one year and nine months and an add-on interest equal to 10% of the initial principal which contains a variable conversion rate with a discount of 30% of the Company’s common stock based on the terms included in the Variable Note. The Variable Note contains a prepayment option which enables the Company to prepay the note for a period of 0-180 days subsequent to issuance at a premium of 125%. The gross amount of this Variable Note outstanding is $302,500 as of March 31, 2016. March 31, December 31, 2016 2015 Notes payable at beginning of period $ 2,333,751 $ 1,377,416 Notes payable issued 302,500 1,586,250 Repayments of notes payable in cash (125,000) (138,000) Less amounts converted to equity (125,000) (491,915) Notes payable at end of period 2,386,251 2,333,751 Less debt discount (843,164) (799,307) $ 1,543,087 $ 1,534,444 Notes payable issued to related parties $ 245,000 $ 245,000 Notes payable issued to non-related parties $ 1,298,087 $ 1,289,444 The maturity dates on the notes payable are as follows: Notes to 12 months ending, Related parties Non-related parties Total March 31, 2017 $ 245,000 $ 1,328,750 $ 1,573,750 March 31, 2018 $ - $ 762,500 $ 762,500 March 31, 2019 $ - $ 50,000 $ 50,000 $ 245,000 $ 2,141,250 $ 2,386,250 Current notes payable $ 245,000 $ 1,328,750 $ 1,573,750 Long term notes payable $ - $ 812,500 $ 812,500 Derivative Liability The Company has issued Variable Debentures which contained variable conversion rates based on unknown future prices of the Company’s common stock. This results in a conversion feature. The Company measures the conversion feature using the Black-Scholes option valuation model using the following assumptions: Three months ended March 31, 2016 2015 Expected term 3 to 28 months 0 Exercise price $0.07 to $0.26 $0.00 Expected volatility 221% to 264% 0% Expected dividends 0 0 Risk-free interest rate 0.59% to 1.06% 0.00% Forfeitures 0 0 The time period over which the Company will be required to evaluate the fair value of the conversion feature is nine to twenty-four months or conversion. The assumptions used in determining fair value represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management’s judgment. As a result, if factors change, including changes in the market value of the Company’s common stock, managements’ assessment or significant fluctuations in the volatility of the trading market for the Company’s common stock, the Company’s fair value estimates could be materially different in the future. The Company computes the fair value of the derivative liability at each reporting period and the change in the fair value is recorded as non-cash expense or non-cash income. The key component in the value of the derivative liability is the Company’s stock price, which is subject to significant fluctuation and is not under its control. The resulting effect on net loss is therefore subject to significant fluctuation and will continue to be so until the Company’s Variable Debentures, which the convertible feature is associated with, are converted into common stock or paid in full with cash. Assuming all other fair value inputs remain constant, the Company will record non-cash expense when its stock price increases and non-cash income when its stock price decreases. As of March 31, 2016 and December 31, 2015, the balances of the Derivative Liability are as follows: Derivative Liability Balance December 31, 2015 $ 3,973,542 Issuance of convertible debt 628,132 Settlements by debt extinguishment (236,439) Change in estimated fair value (1,024,602) Balance March 31, 2016 $ 3,340,633 Long Term Loan The Company has financed the purchase of an automobile. The maturity dates on the loan are as follows: Maturity dates of long term debt Twelve months ending, March 31, 2017 $ 12,121 March 31, 2018 $ 12,488 March 31, 2019 $ 1,064 $ 25,673 Current portion $ 12,121 Long term portion $ 13,552

Note 4 - Shareholders' Deficit

Note 4 - Shareholders' Deficit	3 Months Ended
	Mar. 31, 2016
Equity [Abstract]
Note 4 - Shareholders' Deficit	Note 4 - Shareholders’ Deficit Common Stock The Company has entered into consulting agreements with various consultants for service to be provided to the Company. The agreements stipulate a monthly fee and a certain number of shares that the consultant vests in over the term of the contract. The consultant is issued a prorated number of shares of common stock at the beginning of the contract, which the consultant earns over a three-month period. At the anniversary of each quarter, the consultant is issued a new allotment of common stock during the first 3 years of engagement. In accordance with ASC 505-50 – Equity-Based Payment to Non-Employees, the common stock shares issued to the consultant are valued upon their vesting, with interim estimates of value as appropriate during the vesting period. During the three months ended March 31, 2016, the Company issued 901,504 shares of common stock with a value of $427,306 related to these consulting agreements. During the three months ended March 31, 2016, the Company issued 150,000 shares of common stock related to lock-up agreements valued at $65,500 and 512,273 shares of common stock for cash in the amount of $107,025. During the three months ended March 31, 2016, the Company issued pursuant to a private placement offering 1,851,977 shares of common stock and the same number of warrants for cash of $271,250 and conversion of notes and accrued interest in the amount of $269,416. Also, during the three months ended March 31, 2016, the Company issued 70,110 shares of common stock valued at $25,651 related to the extension of outstanding notes. Series AA Preferred Shares On February 22, 2013, the Board of Directors of the Company authorized an amendment to the Company’s Articles of Incorporation, as amended (the “Articles of Incorporation”), in the form of a Certificate of Designation that authorized the issuance of up to one million (1,000,000) shares of a new series of preferred stock, par value $0.0001 per share, designated “Series AA Super Voting Preferred Stock,” for which the board of directors established the rights, preferences and limitations thereof. Each holder of outstanding shares of Series AA Super Voting Preferred Stock shall be entitled to one hundred thousand (100,000) votes for each share of Series AA Super Voting Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company. As of March 31, 2016, there were 1,000 shares of Series AA Preferred stock outstanding.

Note 5 - Related Party Transact

Note 5 - Related Party Transactions	3 Months Ended
	Mar. 31, 2016
Related Party Transactions [Abstract]
Note 5 - Related Party Transactions	Note 5 – Related Party Transactions Two officers and executives of the Company have entered into note payable agreements with the Company. The balance of notes payable from related parties at March 31, 2016 is $245,000. From time-to-time officers of the Company advance monies to the Company to cover costs. During the three months ended March 31, 2016, officers advanced $5,508 of funds to the Company, and $10,300 were repaid to the officers The balance of short-term advances due to two officers and executives of the Company at March 31, 2016 is $0.

Note 6 - Fair Value Measurement

Note 6 - Fair Value Measurements	3 Months Ended
	Mar. 31, 2016
Fair Value Disclosures [Abstract]
Note 6 - Fair Value Measurements	Note 6 – Fair Value Measurements Accounting guidance on fair value measurements and disclosures defines fair value, establishes a framework for measuring the fair value of assets and liabilities using a hierarchy system, and defines required disclosures. It clarifies that fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the market in which the reporting entity transacts business. The Company's balance sheet contains derivative and warrant liabilities that are recorded at fair value on a recurring basis. The three-level valuation hierarchy for disclosure of fair value is as follows: Level 1: uses quoted market prices in active markets for identical assets or liabilities. Level 2: uses observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: uses unobservable inputs that are not corroborated by market data. The fair value of the Company’s recorded derivative liability is determined based on unobservable inputs that are not corroborated by market data, which require a Level 3 classification. A Black-Scholes option valuation model was used to determine the fair value. The Company records derivative liability on the condensed consolidated balance sheets at fair value with changes in fair value recorded in the condensed consolidated statements of operation. The following table presents changes in the liabilities with significant unobservable inputs (Level 3) for the three months ended March 31, 2016: Fair Value Measurements Using Quoted Prices in Significant Other Significant Active Markets for Observable Unobservable Identical Assets Inputs Inputs (Level 1) (Level 2) (Level 3) Total As of March 31, 2016 Derivative liability $ - $ - $ 3,340,633 $ 3,340,633 Total $ - $ - $ 3,340,633 $ 3,340,633

Note 7 - Subsequent Events

Note 7 - Subsequent Events	3 Months Ended
	Mar. 31, 2016
Subsequent Events [Abstract]
Note 7 - Subsequent Events	Note 7 – Subsequent Events Subsequent to March 31, 2016, an aggregate of 750,000 shares of restricted common stock were issued as compensation to independent contractors. Subsequent to March 31, 2016, the Company issued 540,810 shares of its restricted common stock pursuant to a Private Placement Memorandum and private offerings. Subsequent to March 31, 2016, an aggregate of 36,000 shares of common stock were issued for leak out agreements. As a result of these issuances the total number of shares outstanding is 109,616,075.

Note 1 - Organization and Nat14

Note 1 - Organization and Nature of Business (Policies)	3 Months Ended
	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements have been presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Article 8 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. The condensed consolidated financial statements as of March 31, 2016 and 2015 are unaudited; however, in the opinion of management such interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the periods presented. The results of operations for the period presented are not necessarily indicative of the results that might be expected for future interim periods or for the full year. The consolidated financial statements of the Company include the accounts of ETI and IPR as of March 14, 2012; Aviva as of April 2, 2013; and WeHealAnimals as of November 16, 2013. All significant intercompany accounts and transactions are eliminated in consolidation.
Going Concern	Going Concern These accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for a period following the date of these consolidated financial statements. The Company has raised approximately $650,000 in debt and equity financing for the period January 1, 2016 to March 31, 2016. The Company is raising additional capital through debt and equity securities in order to continue the funding of its operations. However, there is no assurance that the Company can raise enough funds or generate sufficient revenues to pay its obligations as they become due, which raises substantial doubt about our ability to continue as a going concern. No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management and has initiated a private placement offering to raise capital through the sale of its common stock and is seeking out profitable companies. Although, uncertainty exists as to whether the Company will be able to generate enough cash from operations to fund the Company’s working capital needs or raise sufficient capital to meet the Company’s obligations as they become due, no adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty.
Net Income (Loss) per Share	Net Income (Loss) per Share For the three month period ending March 31, 2016, the Company had 7,747,422 of weighted average common shares relating to the convertible debt, under the if-converted method, however, these shares are not dilutive because the Company recorded a loss during the fiscal quarter. For the three months ended March 31, 2015, the Company had no dilutive securities.
Recent Accounting Standard Updates	Recent Accounting Standard Updates The Company is not aware of any recently issued accounting pronouncements that when adopted will have a material effect on the Company’s financial position or results of its operations.

Note 2 - Property, Plant and 15

Note 2 - Property, Plant and Equipment (Tables)	3 Months Ended
	Mar. 31, 2016
Property, Plant and Equipment [Abstract]
Summary of property, plant and equipment	March 31, December 31, 2016 2015 Autos $ 64,458 $ 64,458 Medical equipment 5,000 5,000 Other equipment 8,774 8,774 78,232 78,232 Less accumulated depreciation 50,533 46,575 $ 27,699 $ 31,657

Note 3 - Notes Payable and Lo16

Note 3 - Notes Payable and Long Term Loan (Tables)	3 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Schedule of notes payable	March 31, December 31, 2016 2015 Notes payable at beginning of period $ 2,333,751 $ 1,377,416 Notes payable issued 302,500 1,586,250 Repayments of notes payable in cash (125,000) (138,000) Less amounts converted to equity (125,000) (491,915) Notes payable at end of period 2,386,251 2,333,751 Less debt discount (843,164) (799,307) $ 1,543,087 $ 1,534,444 Notes payable issued to related parties $ 245,000 $ 245,000 Notes payable issued to non-related parties $ 1,298,087 $ 1,289,444
The maturity dates on the notes payable	The maturity dates on the notes payable are as follows: Notes to 12 months ending, Related parties Non-related parties Total March 31, 2017 $ 245,000 $ 1,328,750 $ 1,573,750 March 31, 2018 $ - $ 762,500 $ 762,500 March 31, 2019 $ - $ 50,000 $ 50,000 $ 245,000 $ 2,141,250 $ 2,386,250 Current notes payable $ 245,000 $ 1,328,750 $ 1,573,750 Long term notes payable $ - $ 812,500 $ 812,500
Conversion Feature Derivative Liability	Three months ended March 31, 2016 2015 Expected term 3 to 28 months 0 Exercise price $0.07 to $0.26 $0.00 Expected volatility 221% to 264% 0% Expected dividends 0 0 Risk-free interest rate 0.59% to 1.06% 0.00% Forfeitures 0 0
Derivative Liabilities	Derivative Liability Balance December 31, 2015 $ 3,973,542 Issuance of convertible debt 628,132 Settlements by debt extinguishment (236,439) Change in estimated fair value (1,024,602) Balance March 31, 2016 $ 3,340,633
Schedule of future minimum payments	Maturity dates of long term debt Twelve months ending, March 31, 2017 $ 12,121 March 31, 2018 $ 12,488 March 31, 2019 $ 1,064 $ 25,673 Current portion $ 12,121 Long term portion $ 13,552

Note 6 - Fair Value Measureme17

Note 6 - Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2016
Fair Value Disclosures [Abstract]
Changes in the Liabilities With Significant Unobservable Inputs	Fair Value Measurements Using Quoted Prices in Significant Other Significant Active Markets for Observable Unobservable Identical Assets Inputs Inputs (Level 1) (Level 2) (Level 3) Total As of March 31, 2016 Derivative liability $ - $ - $ 3,340,633 $ 3,340,633 Total $ - $ - $ 3,340,633 $ 3,340,633

Note 1 - Nature of Business and

Note 1 - Nature of Business and Summary of Significant Accounting Policies (Details Narrative)	3 Months Ended
	Mar. 31, 2016USD ($)shares
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Weighted-average common shares relating to the convertible debt | shares	7,747,422
Debt and equity financing raised | $	$ 650,000

Note 2 - Property, Plant and 19

Note 2 - Property, Plant and Equipment (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Property and Equipment Gross	$ 78,232	$ 78,232
Less accumulated depreciation	50,533	46,575
Property and Equipment, Net	27,699	31,657
Automobiles
Property, Plant and Equipment [Line Items]
Property and Equipment Gross	64,458	64,458
Medical Equipment
Property, Plant and Equipment [Line Items]
Property and Equipment Gross	5,000	5,000
Other Equipment
Property, Plant and Equipment [Line Items]
Property and Equipment Gross	$ 8,774	$ 8,774

Note 2 - Property, Plant and 20

Note 2 - Property, Plant and Equipment (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Depreciation and amortization expense	$ 3,958	$ 3,640

Note 3 - Notes Payable and Lo21

Note 3 - Notes Payable and Long Term Loan - Notes Payable (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Debt Disclosure [Abstract]
Notes payable at beginning of period	$ 1,377,416
Notes payable issued for cash	302,500	$ 1,586,250
Repayments of notes payable in cash	(125,000)	(138,000)
Notes payable at end of period	2,386,251	1,377,416
Less debt discount	(843,164)	(799,307)
Notes payable, Net	1,543,087	1,534,444
Notes payable issued to related parties	245,000	245,000
Notes payable issued to non-related parties	$ 1,178,975	$ 1,261,790

Note 3 - Notes Payable and Lo22

Note 3 - Notes Payable and Long Term Loan - Maturity Dates on notes Payable (Details)	Mar. 31, 2016USD ($)
Mar 31, 2017	$ 12,121
Mar 31, 2018	12,488
Mar 31, 2019	1,064
Total	25,673
Related Parties
Mar 31, 2017	245,000
Mar 31, 2018	0
Mar 31, 2019	0
Total	245,000
Non-related Parties
Mar 31, 2017	1,328,750
Mar 31, 2018	762,500
Mar 31, 2019	50,000
Total	2,141,250
Notes Payable
Mar 31, 2017	1,573,750
Mar 31, 2018	762,500
Mar 31, 2019	50,000
Total	$ 2,386,250

Note 3 - Notes Payable and Lo23

Note 3 - Notes Payable and Long Term Loan - Conversion Feature Derivative Liability (Details) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Debt Disclosure [Abstract]
Expected term, Max	3 years	0 years
Expected term, Min	28 months	0 years
Exercise price, Max	$ .26	$ 0
Exercise price, Min	$ .07	$ 0
Expected volatility, Max	264.00%	0.00%
Expected volatility, Min	221.00%	0.00%
Expected dividends	$ 0	$ 0
Risk-free interest rate, Max	1.06%	0.00%
Risk-free interest rate, Min	0.59%	0.00%
Forfeitures	$ 0	$ 0

Note 3 - Notes Payable and Lo24

Note 3 - Notes Payable and Long Term Loan - Derivative Liabilities (Details) - USD ($)	3 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Liabilities With Significant Unobservable Inputs	$ 3,340,633	$ 3,973,542
Change in estimated fair value	(1,024,602)
Settlements by debt extinguishment	$ (236,439)

Note 3 - Notes Payable and Lo25

Note 3 - Notes Payable and Long Term Loan - Schedule of Future Minimum Payments on Auto Loan (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Long term auto loan, Maturity dates
Mar 31, 2017	$ 12,121
Mar 31, 2018	12,488
Mar 31, 2019	1,064
Total	25,673
Current portion	12,121	$ 12,031
Long term portion	$ 13,552	$ 16,616

Note 4 - Shareholders' Deficit

Note 4 - Shareholders' Deficit (Details) - USD ($)	3 Months Ended
	Jun. 30, 2016	Mar. 31, 2016	May. 27, 2016	Dec. 31, 2015
Equity [Abstract]
Share issued for services		$ 492,700
Share issued for service rendered, shares	750,000
Shares issued with notes payable		25,643
Issuance of shares of restricted common stock	540,810
Notes payable		$ 2,386,251		$ 1,377,416
Shares issued in extension agreement on note payable		70,110
Common stock, shares outstanding		108,289,265	109,616,075	104,803,401

Note 5 - Related Party Transa27

Note 5 - Related Party Transactions (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Related Party Transactions
Related party advances	$ 5,508
Related party advances paid back during period	10,300
Short term advances due to related party	0
Notes payable - related party	$ 245,000	$ 245,000

Note 6 - Fair Value Measureme28

Note 6 - Fair Value Measurements - Balances of Liabilities Measured At Fair Value (Details)	Mar. 31, 2016USD ($)
Quoted Prices In Active Markets For Identical Assets (Level1)
Derivative liability	$ 0
Total	0
SignificantOtherObservableInputs (Level2)
Derivative liability	0
Total	0
SignificantOtherUnobservableInputs (Level3)
Derivative liability	3,340,633
Total	3,340,633
Total Derivative Liability
Derivative liability	3,340,633
Total	$ 3,340,633

Note 7 - Subsequent Events (Det

Note 7 - Subsequent Events (Details) - USD ($)	3 Months Ended
	Jun. 30, 2016	May. 27, 2016	Mar. 31, 2016	Dec. 31, 2015
Subsequent Event
Issuance of shares of restricted common stock, shares	540,810
Issuance of shares for leak out agreements	36,000
Notes payable			$ 2,386,251	$ 1,377,416
Share issued for service rendered, shares	750,000
Shares issued in extension agreement on note payable			70,110
Common stock, shares outstanding		109,616,075	108,289,265	104,803,401